Submit an IND for the type 1 diabetes cells and immunoprotective device program

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 2 Nov 2021
Due: 31 Dec 2022

Deadline
Met
Late
Not met
Today

What the company said

“Vertex expects to submit an IND for the cells and device program in 2022.”

SourceVertex Pharmaceuticals Form 8-K press release, 2021-11-02
FilingSEC filing index
Deadline as statedin 2022
Deadline used31 Dec 2022, the last day of the stated period
TypeRegulatory
Permanent referenceKI-C-2021-VRTX-006504
Cite as https://keptindex.org/c/KI-C-2021-VRTX-006504/ — this address never changes.

What we found

Evidence strength A What the grades mean

A February 2023 8-K states Vertex submitted a U.S. IND for the VX-264 cells plus device program in December 2022, within the 2022 deadline.

A
Vertex Pharmaceuticals 8-K filed 2023-02-07 Regulatory filing · published 7 Feb 2023 · retrieved 10 Oct 2026 · kept permanently by the SEC
“In December 2022, Vertex submitted an IND in the U.S. and a Clinical Trial Application (CTA) in Canada, for VX-264, the cells plus device program.” ✓ confirmed on the page
A
Vertex Pharmaceuticals 10-K filed 2023-02-10 Regulatory filing · published 10 Feb 2023 · retrieved 10 Oct 2026 · kept permanently by the SEC
“In addition, we submitted an IND for our second program in T1D, VX-264, in which the implanted islet cells are encapsulated in an immunoprotective device.” ✓ confirmed on the page

Market reaction: the shares moved -3.7% against the S&P 500 over the three sessions around the disclosure (6 Feb 2023 to 9 Feb 2023). What this measures

Checked 10 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

2 versions

Version 1 · original · stated 2 Nov 2021

Deadline 31 Dec 2022 (“in 2022”) · wording expected
Version 2 · stated 5 May 2022

Deadline 31 Dec 2022 (“in 2022”) · wording firm

“Vertex is on track to submit an IND for the cells plus device program in 2022.”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Regulatory filing
Indicative materiality: Medium rules
Action: Submit
Deliverable: IND submission for T1D cells and device program
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Vertex Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.